

Clinical Trials Summary for out of hours Important Reference

Acronym study title	Astefania - WO42633
Study Details	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
Principal Investigator or PI Sub PI's	PI - Dr Martin Hogg Sub Investigator - Dr Elaine Young
Research Nurse Team	Research Nurse - Haiyan Huang CTSO - Nathan Fish
Drug therapy	Patients will be randomized to one of the following treatment arms in a 1:1 ratio: Arm A: Atezolizumab placebo 1200 mg IV Q3W and trastuzumab emtansine 3.6 mg/kg IV Q3W for 14 cycles Arm B: Atezolizumab 1200 mg IV Q3W and trastuzumab emtansine 3.6 mg/kg IV Q3W for 14 cycles
In the event that a patient calls this hotline for advise	www.healthierlsc.co.uk/application/files/1216/2080/9018/Kadcyla_April_2021.pdf www.healthierlsc.co.uk/application/files/8715/8868/2318/Atezolizumab_abraxane_v3.pdf https://www.healthierlsc.co.uk/application/files/8015/1810/1058/Trastuzumab_sc_V3.pdf